Thalidomide BMS (Thalidomide)
Immunomodulatory agent for multiple myeloma
Quick Facts: Thalidomide BMS
Key Takeaways
- Pregnancy prevention is mandatory: Thalidomide causes severe birth defects. A strict programme including contraception and regular pregnancy tests must be followed by all patients of childbearing potential
- Used as first-line combination therapy: Given together with melphalan and prednisone (MPT regimen) for newly diagnosed multiple myeloma in patients who cannot receive high-dose chemotherapy
- Monitor for peripheral neuropathy: Nerve damage in hands and feet is a very common side effect that may be irreversible. Report tingling, numbness, or pain to your doctor immediately
- Increased blood clot risk: Thalidomide increases the risk of deep vein thrombosis (DVT) and pulmonary embolism. Preventive anticoagulation may be prescribed
- Take at bedtime: The medicine causes drowsiness, so it should be taken as a single dose at bedtime to minimise daytime sleepiness
What Is Thalidomide BMS and What Is It Used For?
Thalidomide BMS contains the active substance thalidomide, an immunomodulatory agent used in combination with melphalan and prednisone to treat newly diagnosed multiple myeloma in adults who are 65 years or older, or in younger patients who cannot receive high-dose chemotherapy.
Thalidomide belongs to a class of medicines known as immunomodulatory drugs (IMiDs). It was originally developed in the 1950s as a sedative but was withdrawn from the market after it was discovered to cause severe birth defects. Decades later, researchers identified its potent anti-cancer properties, leading to its reintroduction under strict regulatory controls for the treatment of multiple myeloma.
Multiple myeloma is a cancer of the plasma cells, a type of white blood cell found in the bone marrow. In this disease, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and producing abnormal proteins that can damage bones, kidneys, and the immune system. While multiple myeloma is generally not curable, treatment can significantly reduce symptoms and prolong survival. Periods where the disease is well controlled are called remission.
Thalidomide works through several complementary mechanisms to fight myeloma. It inhibits the growth of new blood vessels that feed tumours (anti-angiogenesis), directly triggers cancer cell death (apoptosis), and stimulates the patient's own immune system – particularly T cells and natural killer cells – to attack myeloma cells. Additionally, thalidomide modulates the bone marrow microenvironment by reducing levels of tumour necrosis factor alpha (TNF-α) and other inflammatory cytokines that support myeloma cell survival.
The combination of thalidomide with melphalan (a chemotherapy drug) and prednisone (a corticosteroid) is known as the MPT regimen. This combination has been shown in multiple randomised controlled trials, including the landmark IFM 99-06 and IFM 01-01 trials, to significantly improve response rates and overall survival compared with melphalan and prednisone alone in elderly patients with newly diagnosed myeloma.
How Thalidomide BMS Works
- Anti-angiogenesis: Prevents the formation of new blood vessels that supply nutrients to myeloma tumours
- Direct anti-tumour effect: Induces apoptosis (programmed cell death) in myeloma cells
- Immune stimulation: Enhances T-cell and natural killer cell activity against cancer cells
- Microenvironment modulation: Reduces TNF-α and other pro-inflammatory cytokines in the bone marrow
What Should You Know Before Taking Thalidomide BMS?
Before starting Thalidomide BMS, it is critical to understand the pregnancy prevention requirements, blood clot risks, and potential for nerve damage. This medicine must never be taken during pregnancy as it causes severe birth defects and fetal death.
Contraindications
You must not take Thalidomide BMS if any of the following apply to you:
- Pregnancy: If you are pregnant, suspect you may be pregnant, or are planning to become pregnant. Thalidomide causes severe birth defects and fetal death
- Childbearing potential without contraception: If you are of childbearing potential and not following the mandatory pregnancy prevention programme with effective contraception
- Allergy: If you are allergic to thalidomide or any of the other ingredients in the capsules
Even a single capsule of thalidomide taken during pregnancy can cause serious birth defects. These may include shortened arms or legs, malformed hands or feet, eye and ear defects, and damage to internal organs. Thalidomide must never be taken during pregnancy. Both male and female patients must follow strict contraceptive measures.
Pregnancy Prevention Programme
Due to thalidomide's severe teratogenic effects, all patients must adhere to a comprehensive pregnancy prevention programme. This programme is a legal and medical requirement in all countries where thalidomide is authorised.
For women of childbearing potential:
- Pregnancy tests must be performed before treatment, every 4 weeks during treatment, and 4 weeks after stopping treatment
- At least one highly effective method of contraception must be used for at least 4 weeks before starting treatment, throughout the entire treatment period, and for at least 4 weeks after stopping
- Your doctor will confirm at each prescription that all necessary precautions have been taken
- If you miss a menstrual period, experience unexpected bleeding, or suspect you may be pregnant, you must stop taking thalidomide immediately and inform your doctor
For men taking thalidomide:
- Thalidomide passes into semen. You must always use a condom during treatment and for at least 7 days after stopping, even if you have had a vasectomy
- You must not donate sperm during treatment or for at least 7 days after stopping
- If your female partner becomes pregnant while you are taking thalidomide, inform your doctor immediately
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Thalidomide BMS if any of the following apply to you:
- Blood clots: If you have had a heart attack, previous blood clots, or if you smoke, have high blood pressure, or high cholesterol. Thalidomide significantly increases the risk of venous and arterial thromboembolism
- Peripheral neuropathy: If you have or have had nerve damage causing tingling, abnormal coordination, or pain in hands or feet. This is a very common and potentially irreversible side effect
- Heart conditions: If you have slow heartbeat (bradycardia) or heart failure
- Pulmonary hypertension: If you have high blood pressure in the lung arteries
- Low blood counts: If you have reduced white blood cells (neutropenia) with fever and infection, or low platelets
- Liver or kidney problems: Including abnormal liver function tests
- Severe skin reactions: If you have previously experienced Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome
- Viral infections: Particularly varicella zoster, hepatitis B, or HIV. Thalidomide can reactivate latent viral infections
- Tumour lysis syndrome: Your doctor may monitor you for this condition, where rapid tumour breakdown causes dangerous metabolic changes
Tell your doctor immediately if you experience blurred vision, vision loss, double vision, difficulty speaking, weakness in an arm or leg, changes in walking or balance, persistent numbness, memory loss, or confusion. These may be signs of PML, a rare but serious brain condition.
Blood donation: You must not donate blood during treatment or for at least 7 days after treatment ends.
Children and adolescents: Thalidomide BMS is not recommended for use in children and adolescents under 18 years of age.
Pregnancy and Breastfeeding
Thalidomide is one of the most well-documented human teratogens. The thalidomide tragedy of the late 1950s and early 1960s resulted in severe birth defects in thousands of children worldwide, leading to its withdrawal from the market and fundamentally changing drug safety regulations globally.
If a patient becomes pregnant while taking thalidomide, the medicine must be stopped immediately and the doctor must be informed. The patient should be referred to a physician specialising in teratology for evaluation.
Breastfeeding: You must not breastfeed while taking Thalidomide BMS, as it is not known whether thalidomide passes into breast milk.
Driving and operating machinery: Thalidomide can cause dizziness, fatigue, drowsiness, and blurred vision. Do not drive or operate machinery if you experience any of these effects.
How Does Thalidomide BMS Interact with Other Drugs?
Thalidomide interacts with several drug classes, most importantly sedatives, anticoagulants, and medicines that cause bradycardia or neuropathy. Alcohol should be avoided as it potentiates the sedative effects. Always inform your doctor about all medicines you are taking.
Thalidomide can interact with a number of other medications, either by enhancing their effects or by increasing the risk of side effects. It is essential to tell your doctor about all medicines you take, including over-the-counter products and herbal remedies.
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Sedatives, anxiolytics, hypnotics | Enhanced sedation and CNS depression | Major – avoid or use with extreme caution |
| Opioid analgesics | Increased drowsiness and respiratory depression risk | Major – dose adjustment may be required |
| Antihistamines (H1 blockers) | Enhanced sedative effects | Moderate – monitor for excessive drowsiness |
| Beta-blockers, anticholinesterases | Additive bradycardia (slow heart rate) | Moderate – monitor heart rate |
| Digoxin | Additive cardiac effects | Moderate – monitor ECG and digoxin levels |
| Warfarin and anticoagulants | Altered coagulation parameters | Moderate – monitor INR closely |
| Hormonal contraceptives | Possible reduced contraceptive efficacy | Major – use additional barrier method |
| Other neurotoxic drugs | Additive peripheral neuropathy risk | Major – avoid combination when possible |
| Alcohol | Potentiated sedation and CNS depression | Major – avoid alcohol completely |
Major Interactions
The most clinically significant interactions involve medicines that cause sedation. Thalidomide itself is a potent sedative, and combining it with benzodiazepines, opioids, barbiturates, antipsychotics, or alcohol can lead to profound central nervous system depression. Patients should be warned about the additive sedative effects and advised to avoid driving or operating heavy machinery.
Hormonal contraceptives may have reduced efficacy when used with thalidomide. Given the catastrophic consequences of pregnancy during thalidomide treatment, women of childbearing potential should use at least one additional barrier method of contraception alongside hormonal methods.
Moderate Interactions
Medicines that slow the heart rate (beta-blockers, anticholinesterases, calcium channel blockers) can have additive effects with thalidomide, potentially causing clinically significant bradycardia. Heart rate should be monitored regularly. Similarly, patients on anticoagulants such as warfarin should have their INR monitored more frequently, as thalidomide may alter coagulation parameters.
What Is the Correct Dosage of Thalidomide BMS?
The standard dose of Thalidomide BMS is 200 mg daily for adults under 75 years, and 100 mg daily for adults over 75 years. It is taken as a single dose at bedtime in 6-week treatment cycles alongside melphalan and prednisone.
Always take Thalidomide BMS exactly as your doctor or pharmacist has told you. The dose and duration of treatment will be tailored to your individual needs, including your age, weight, kidney function, and tolerance of the medicine.
| Patient Group | Recommended Dose | Special Instructions |
|---|---|---|
| Adults under 75 years | 200 mg (4 × 50 mg capsules) once daily | Take at bedtime as single dose |
| Adults 75 years and over | 100 mg (2 × 50 mg capsules) once daily | Take at bedtime as single dose |
| Children and adolescents | Not recommended | Safety and efficacy not established under 18 years |
Treatment Cycles
Thalidomide is taken daily as part of a 6-week treatment cycle. Within each cycle, melphalan and prednisone are taken on days 1 through 4, while thalidomide is taken continuously every day throughout the 6-week period. Your doctor will determine how many treatment cycles you need based on your response to therapy and how well you tolerate the medicine.
How to Take the Capsules
- Swallow the capsules whole with a full glass of water
- Do not crush, open, or chew the capsules
- Take as a single dose at bedtime to minimise daytime drowsiness
- When removing capsules from the blister pack, press on one end only – do not press in the middle as this may break the capsule
- If powder from a broken capsule contacts the skin, wash the area immediately and thoroughly with soap and water
- Healthcare professionals and caregivers should wear disposable gloves when handling blisters or capsules
Missed Dose
If you forget to take Thalidomide BMS at the usual time:
- Less than 12 hours late: Take the missed dose immediately
- More than 12 hours late: Do not take the missed capsules. Wait and take your next dose at the usual time the following day
Do not take a double dose to make up for a forgotten dose.
Overdose
If you take more Thalidomide BMS than prescribed, contact your doctor or go to the nearest hospital emergency department immediately. If possible, bring the medicine packaging and this information with you. Symptoms of overdose may include severe drowsiness, confusion, and loss of consciousness.
What Are the Side Effects of Thalidomide BMS?
The most common side effects of Thalidomide BMS include peripheral neuropathy (nerve damage), constipation, drowsiness, dizziness, tremor, and low blood cell counts. Serious side effects include blood clots, severe skin reactions, and increased risk of secondary cancers. Report any new or worsening symptoms to your doctor promptly.
Like all medicines, Thalidomide BMS can cause side effects, although not everybody gets them. Some side effects can be serious and may require immediate medical attention.
- Severe skin reactions: rash with or without blisters, sores in mouth/throat/eyes/genitals, swelling, fever, or flu-like symptoms (signs of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome)
- Severe allergic reactions: widespread hives, swelling of face/mouth/eyes, difficulty breathing, or itching (anaphylaxis or angioedema)
Very Common
Affects more than 1 in 10 patients
- Peripheral neuropathy (tingling, numbness, pain in hands/feet)
- Constipation
- Dizziness
- Drowsiness or fatigue
- Tremor (shaking)
- Dysaesthesia (abnormal or reduced sensation)
- Swelling in hands and feet (peripheral oedema)
- Low blood cell counts (anaemia, neutropenia, thrombocytopenia)
Common
Affects up to 1 in 10 patients
- Deep vein thrombosis (DVT) and pulmonary embolism (blood clots)
- Digestive problems: nausea, vomiting, dry mouth, indigestion
- Rash and dry skin
- Febrile neutropenia (low white cells with fever)
- Pancytopenia (low red cells, white cells, and platelets)
- Weakness, faintness, low blood pressure
- Seizures
- Blurred vision
- Pneumonia and other lung infections
- Slow heart rate (bradycardia), heart failure
- Depression, confusion, mood changes, anxiety
- Hearing loss or deafness
- Kidney disease (renal failure)
Uncommon
Affects up to 1 in 100 patients
- Bronchitis (inflammation of airways)
- Gastritis (inflammation of stomach lining)
- Intestinal perforation (hole in the colon), which can cause infection
- Intestinal obstruction
- Orthostatic hypotension (blood pressure drop on standing, may cause fainting)
- Cardiac arrhythmias (heart block or atrial fibrillation)
Rare / Frequency Not Known
Rare or cannot be estimated from available data
- Hypothyroidism (underactive thyroid)
- Sexual dysfunction (including impotence)
- Severe sepsis and septic shock
- Tumour lysis syndrome (dangerous metabolic disturbance from rapid tumour breakdown)
- Liver damage and abnormal liver function tests
- Gastrointestinal bleeding
- Worsening of Parkinson's disease symptoms
- Pancreatitis (inflammation of the pancreas)
- Pulmonary hypertension (high blood pressure in lung arteries)
- Viral reactivation: herpes zoster (shingles), hepatitis B
- Posterior reversible encephalopathy syndrome (PRES)
- Leukocytoclastic vasculitis (inflammation of small blood vessels in the skin)
- Progressive multifocal leukoencephalopathy (PML)
A small proportion of patients with multiple myeloma may develop other types of cancer, particularly haematological malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Treatment with thalidomide may increase this risk. Your doctor will carefully evaluate the benefits and risks of treatment.
Peripheral Neuropathy – Important Information
Peripheral neuropathy is one of the most clinically significant side effects of thalidomide. It manifests as tingling, numbness, burning sensations, pain, or abnormal coordination in the hands and feet. This nerve damage can become severe, painful, and disabling. It typically develops after several months of treatment but can occur earlier.
If you experience any symptoms of neuropathy, inform your doctor immediately. They may reduce your dose or stop treatment. In some cases, the neuropathy may not fully resolve even after stopping thalidomide, and symptoms may persist or only improve slowly over time. Early detection and dose modification are key to preventing irreversible damage.
Blood Clots – Venous Thromboembolism
Thalidomide, particularly when combined with dexamethasone or other chemotherapy agents, significantly increases the risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Warning signs include:
- DVT: Pain or swelling in the legs, especially the lower leg or calf
- Pulmonary embolism: Sudden chest pain, difficulty breathing, or rapid heartbeat
- Heart attack: Chest pain spreading to arms, neck, jaw, or back, with sweating and nausea
- Stroke: Sudden vision or speech difficulties, weakness on one side of the body
Seek emergency medical help immediately if you experience any of these symptoms. Your doctor may prescribe preventive anticoagulation (blood thinners) to reduce this risk.
How Should You Store Thalidomide BMS?
Store Thalidomide BMS out of the sight and reach of children. No special storage conditions are required. Do not use after the expiry date on the packaging. Return unused capsules to a pharmacy after treatment ends.
Keep this medicine out of the sight and reach of children at all times. This is particularly important for thalidomide due to its teratogenic properties.
- Do not use this medicine after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of that month
- No special storage conditions are required – store at room temperature
- Do not use the medicine if you notice any damage to the packaging or signs of tampering
- Unused capsules must be returned to the pharmacy or your doctor after treatment ends. These measures prevent misuse and protect others from accidental exposure
What Does Thalidomide BMS Contain?
Each Thalidomide BMS capsule contains 50 mg of thalidomide as the active substance, in a white hard capsule marked "Thalidomide BMS 50 mg". The capsules are supplied in packs of 28.
Active Ingredient
Each hard capsule contains 50 mg of thalidomide.
Other Ingredients
- Capsule contents: Pregelatinised starch, magnesium stearate
- Capsule shell: Gelatin, titanium dioxide (E171)
- Printing ink: Shellac, black iron oxide (E172), propylene glycol
Appearance and Pack Size
Thalidomide BMS capsules are white hard capsules marked with "Thalidomide BMS 50 mg" in black ink. They are supplied in a carton containing 28 capsules (2 blisters of 14 capsules each).
The marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG, Dublin, Ireland. The capsules are manufactured by Celgene Distribution B.V., Utrecht, The Netherlands.
Frequently Asked Questions About Thalidomide BMS
Thalidomide was originally marketed in the late 1950s as a sedative and morning sickness treatment. It was withdrawn in the early 1960s after causing severe birth defects in thousands of children. However, research in the 1990s revealed that thalidomide has potent anti-cancer and immunomodulatory properties. It was reintroduced under extremely strict safety controls for treating multiple myeloma and other conditions. Today, it is only available through regulated programmes that include mandatory pregnancy prevention measures, making it safe to use when all precautions are followed.
No, you should avoid alcohol while taking Thalidomide BMS. Both thalidomide and alcohol cause drowsiness, and combining them can lead to excessive sedation and impaired judgement. This combination increases the risk of falls, accidents, and respiratory depression. Discuss any questions about alcohol consumption with your doctor.
Treatment duration varies between patients and depends on your response to therapy and how well you tolerate the medicine. Thalidomide is given in 6-week treatment cycles alongside melphalan and prednisone. Your haematologist will regularly assess your progress through blood tests and other examinations to determine how many cycles are appropriate for you. Some patients may receive treatment for several months, while others may continue for a year or longer.
Tingling, numbness, pain, or burning sensations in the hands or feet may be signs of peripheral neuropathy, a very common side effect of thalidomide. Contact your doctor as soon as possible if you experience these symptoms. Early intervention is important because your doctor may need to reduce your dose or stop treatment to prevent the nerve damage from becoming permanent. Do not wait for your next scheduled appointment – neuropathy can progress quickly and may be irreversible if not addressed promptly.
No. You must not donate blood during treatment with Thalidomide BMS or for at least 7 days after stopping treatment. This is to prevent the medicine from being given to a pregnant woman through a blood transfusion. Male patients must also not donate sperm during treatment or for at least 7 days after stopping, as thalidomide passes into semen and could potentially cause harm if the semen is used for conception.
No, although they are related. Lenalidomide (Revlimid) and pomalidomide (Imnovid/Pomalyst) are structurally related compounds known as thalidomide analogues or second- and third-generation immunomodulatory drugs (IMiDs). They were developed to improve on thalidomide's anti-myeloma effects while potentially reducing some side effects. However, all three drugs share the risk of teratogenicity and require strict pregnancy prevention programmes. Your haematologist will choose the most appropriate treatment based on your specific clinical situation.
References
- European Medicines Agency (EMA). Thalidomide BMS – Summary of Product Characteristics. Last updated January 2025. Available at: www.ema.europa.eu
- Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. The Lancet. 2007;370(9594):1209-1218.
- Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Journal of Clinical Oncology. 2009;27(22):3664-3670.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 4.2025.
- Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. European Journal of Haematology. 2010;84(5):379-390.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- NICE Technology Appraisal Guidance TA228. Thalidomide for the first-line treatment of multiple myeloma. National Institute for Health and Care Excellence; 2011 (reviewed 2024).
- Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Research Part C: Embryo Today. 2015;105(2):140-156.
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine. 1999;341(21):1565-1571.
- Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. The Lancet. 2006;367(9513):825-831.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in oncology, haematology, and clinical pharmacology.
Medical Review
All content undergoes rigorous review by board-certified medical specialists. Our editorial process follows international guidelines from EMA, WHO, NCCN, and NICE.
Evidence Standards
We use only evidence level 1A sources: systematic reviews, meta-analyses, and randomised controlled trials published in peer-reviewed medical journals.
Independence
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent and free from advertising influence.
Updates
Articles are reviewed at least annually and updated whenever new evidence or guideline changes emerge. Last review: .